Y-mAbs appoints Doug Gentilcore as Head of DANYELZA Business Unit, focusing on cancer products.

From GlobeNewswire: 2025-01-10 07:35:00

Y-mAbs Therapeutics, Inc. announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. Gentilcore brings over two decades of strategic leadership experience in the pharmaceutical industry to the role. Chief Commercial Officer Sue Smith will be departing the organization, with CEO Michael Rossi thanking her for her contributions. DANYELZA® (naxitamab-gqgk) is indicated for the treatment of pediatric and adult patients with relapsed or refractory high-risk neuroblastoma. Y-mAbs focuses on developing novel radioimmunotherapy and antibody-based cancer products. Forward-looking statements in the press release outline the company’s plans and prospects.



Read more at GlobeNewswire: Y-mAbs Appoints Experienced Commercial Leader as Head of